Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 18/20 | 0.50 |
| ▸ | HTR2B | P41595 | 8/20 | 0.50 |
| ▸ | HTR2A | P28223 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26597131 | 0.77 | HTR2C (0.43) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3234186 | 0.77 | HTR2C (0.67) | HTR2CHTR2BHTR2AALDH1A1CYP1A2 | |
| SCHEMBL25045478 | 0.77 | HTR2C (0.67) | HTR2CHTR2BHTR2AALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL30643257 | 0.76 | HTR2C (0.42) | HTR2CHTR2AALDH1A1CYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL6421970 | 0.75 | HTR2C (0.65) | HTR2CHTR2BHTR2AALDH1A1CYP1A2 | |
| SCHEMBL26095982 | 0.75 | HTR2C (0.45) | HTR2CHTR2BHTR2AALDH1A1CYP1A2 | |
| SCHEMBL996257 | 0.75 | HTR2C (0.45) | HTR2CHTR2BHTR2AALDH1A1CYP1A2 | |
| SCHEMBL2564948 | 0.74 | HTR2C (0.47) | HTR2CHTR2BHTR2AALDH1A1CYP1A2 | |
| SCHEMBL692120 | 0.74 | HTR2C (0.69) | HTR2CHTR2BHTR2A | |
| SCHEMBL2739027 | 0.74 | HTR2C (0.57) | HTR2CHTR2BHTR2AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052929-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | ABBVIE INC. | 2016-02-25 | — | — | US | disclosed |
| US-9133206-B2 | Benzodiazepine and pyridodiazepine derivatives | ABBVIE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140163014-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| US-8673896-B2 | Benzodiazepine and pyridodiazepine derivatives | ABBVIE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110288069-A1 | Benzodiazepine and Pyridodiazepine Derivatives | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288069-A1 | Benzodiazepine and Pyridodiazepine Derivatives | GABRA3, GABRB3, GABRA1 | HTR2C 96/4885HTR2B 87/4885HTR2A 166/4885 |
| US-20160052929-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | GABRA3, GABRB3, GABRA1 | HTR2C 96/4885HTR2B 87/4885HTR2A 166/4885 |
| US-20140163014-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | GABRA3, GABRB3, GABRA1 | HTR2C 96/4885HTR2B 87/4885HTR2A 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.